Dr. Rustgi is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
125 Paterson St
Ste 5100
New Brunswick, NJ 08901Phone+1 732-235-7784Fax+1 732-235-7792
Education & Training
- Johns Hopkins UniversityM.B.A, 2005 - 2009
- Clinical Center at the National Institutes of HealthFellowship, Liver Diseases, 1985 - 1987
- Stanford Health Care-Sponsored Stanford UniversityFellowship, Gastroenterology, 1982 - 1985
- MedStar Health/Georgetown University HospitalResidency, Internal Medicine, 1980 - 1982
- Johns Hopkins University School of MedicineClass of 1979
- Yale UniversityB.A, 1971 - 1975
Certifications & Licensure
- CA State Medical License 1982 - Present
- NY State Medical License 1986 - Present
- FL State Medical License 2022 - 2026
- VA State Medical License 1981 - 2026
- NJ State Medical License 2016 - 2025
- MD State Medical License 2002 - 2017
- PA State Medical License 1983 - 2016
- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Gastroenterology
- Join now to see all
Awards, Honors, & Recognition
- Fellowship Royal College of Physicians (UK), 2020-2022
- Distinguished Professorship Rutgers Robert Wood Johnson Medical School, 2020-2022
- Fellowship American Association for the Study of Liver Diseases, 2020-2022
- Join now to see all
Clinical Trials
- YM443 in Subjects With Functional Dyspepsia Start of enrollment: 2004 Mar 10
- HepeX-B in Post Hepatic Allografts for Treatment of End Stage Liver Disease Due to Hepatitis B Infection
- Study of Nitazoxanide, Peginterferon Alfa-2a and Ribavirin in Treatment-Naive Hepatitis C Patients Start of enrollment: 2008 Mar 01
- Join now to see all
Publications & Presentations
PubMed
- 4586 citationsPeginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial.Michael P. Manns, John G. McHutchison, Stuart C. Gordon, Vinod K. Rustgi, Mitchell L. Shiffman
Lancet. 2001-09-22 - 1071 citationsInterferon Alfa-2b Alone or in Combination with Ribavirin for the Treatment of Relapse of Chronic Hepatitis CGary L. Davis, Rafael Esteban-Mur, Vinod K. Rustgi, John C. Hoefs, Stuart C. Gordon
The New England Journal of Medicine. 1998-11-19 - 27 citationsAssociation of Bariatric Surgery With Cardiovascular Outcomes in Adults With Severe Obesity and Nonalcoholic Fatty Liver Disease.Mohamed I Elsaid, You Li, John F P Bridges, Guy Brock, Carlos D Minacapelli
JAMA Network Open. 2022-10-03
Journal Articles
- New Perspectives and Advances in Risk-Factor Assessment, Diagnosis, and Treatment of Hepatitis C.Rustgi VK, Practical Gastroenterology
- Hepatitis C virus treatment related anemia is associated with higher sustained virologic response rate.Sulkowski MS, Shiffman ML…Rustgi V…et al, Gastroenterology;139 (5): 1602-11, 1611.e1
- Racial differences in hepatitis C treatment eligibility.Melia MT…Rustgi VK…et al, Hepatology: 54(1): 70-8
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- The effect of rat gamma interferon on antipyrine metabolism by the isolated perfused rat liver.Rustgi VK, Suou T, Jones DB, Lisker-Melman M, Vergalla J, Jones EA, Hoofnagle JH, AFCR National Meetings; Clinical Research, 35 (3): 414A, San Diego, CA
- Liver Transplantation for the Alcoholic Patient.Rustgi VK, Transplant Forum pp. 2-4
- Chronic domiciliary respiratory support by portable positive pressure ventilators.Tsou E, Waldhorn R, Rustgi VK, Am. Rev. Resp. Dis. 127: 125
- Join now to see all
Other
- A phase 2 dose-escalation study of albuferon combined with ribavirin in non-responders to prior interferon based therapy for chronic hepatitis C infection.Reddy KR, Rustgi VK, Zeuzem S, Gane E, Lim SG, Jia JD, Belanger B, George S, Harb G, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/easl2006/program/SessionIndex.asp - Valopicitabine (NM283), alone or with peg-interferon, compared to peg Interferon/Ribavirin (PEGIFN/RBV) retreatment in hepatitis C patients with prior non-response to ...Afdhal N, O’Brien C, Godofsky E, Rodriguez-Torres M, Pappas SC, Pockros P… Rustgi VK… et al, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/easl2006/program/SessionIndex.asp - Pre-dosing taribavirin prior to combination therapy with pegylated interferon alfa-2B versus standard combination dosing: 24-week interim results examining safety and ...Palmer M, Rubin R, Rustgi VK, Li D & Murphy B, annual European Association for the Study of the Liver Meeting
http://www.easl.ch/liver-meeting/program/SessionIndex.asp - Join now to see all
Press Mentions
- Study: Bariatric Surgery Reduces Risk of Heart DiseaseNovember 19th, 2022
- Weight-Loss Surgery Slashes Odds for Heart Attack in Very Obese PeopleNovember 16th, 2022
- Bariatric Surgery in NAFLD Tied to Lower Heart Disease RiskOctober 7th, 2022
- Join now to see all
Professional Memberships
- Fellow
Other Languages
- Hindi
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: